News
SILO
0.3960
+1.54%
0.0060
Weekly Report: what happened at SILO last week (0504-0508)?
Weekly Report · 2d ago
Silo Pharma files provisional patent for ibogaine-based therapeutics
TipRanks · 5d ago
Psychedelic: Jefferies initiates Compass Pathways with a Buy rating
TipRanks · 5d ago
Silo Pharma Launches Ibogaine-Based TBI Drug Initiative, Files Patent Amid Growing Psychedelic Therapy Push
Benzinga · 6d ago
Silo Pharma files provisional patent for ibogaine-based traumatic brain injury treatment
PUBT · 6d ago
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
Barchart · 6d ago
Weekly Report: what happened at SILO last week (0427-0501)?
Weekly Report · 05/04 09:42
Psychedelic: FDA awards Compass Pathways priority review voucher
TipRanks · 04/30 18:56
Silo Pharma commends US federal push to fast-track psychedelic PTSD therapies
PUBT · 04/29 13:10
SILO PHARMA INC - FDA GRANTS IND CLEARANCE TO DEMERX NB FOR NORIBOGAINE TARGETING ALCOHOL USE DISORDER
Reuters · 04/29 13:08
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
Barchart · 04/29 08:08
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 04/27 17:05
Weekly Report: what happened at SILO last week (0420-0424)?
Weekly Report · 04/27 09:43
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 04/23 17:05
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 04/23 12:07
Silo Pharma Expands Into AI Agent Market With Qwikagents Platform Acquisition; Stock Down
NASDAQ · 04/23 08:10
Silo Pharma expands into AI technology with Qwikagents asset purchase
TipRanks · 04/22 21:10
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 04/22 21:05
Silo Pharma buys Qwikagents.ai platform assets, expands into AI agent market
PUBT · 04/22 20:41
RMA INC - TO SUBMIT SPC-15’S IND TO FDA AND LAUNCH OUR FIRST-IN-HUMAN TRIAL AFTER FDA APPROVAL
Reuters · 04/22 20:15
More
Webull provides a variety of real-time SILO stock news. You can receive the latest news about Silo Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.